Redox-generated isoprostanes are associated with residual platelet activity in aspirin-treated patients with stable coronary heart disease

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 12, 2010, Pages 2662-2670

  Schwedhelm, E ^a   Bierend, A ^a   Maas, R ^a,b   Trinks, R ^a   Kom, G D ^a   Tsikas, D ^c   Boger R H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Aspirin; Isoprostanes; Platelet aggregation; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; COLLAGEN; CREATININE; CYCLOOXYGENASE 1; ISOPROSTANE; PROSTAGLANDIN F2 ALPHA; SALICYLIC ACID; SALICYLURIC ACID; THROMBOXANE B2;

AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXCRETION; FEMALE; HUMAN; IN VITRO STUDY; INFLAMMATION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

AGED; ASPIRIN; BLOOD PLATELETS; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; ISOPROSTANES; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; PLATELET AGGREGATION INHIBITORS; TANDEM MASS SPECTROMETRY;

EID: 78649990318     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04117.x     Document Type: Article

References (44)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-7.
3. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK, Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3: 1309-11.
4. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
5. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195-8.
6. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schrör K. Towards a definition of aspirin resistance: a typological approach. Platelets 2002; 13: 37-40.
7. Hohlfeld T, Zimmermann N, Weber AA, Jessen G, Weber H, Schrör K, Höltje HD, Ebel R. Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. J Thromb Haemost 2008; 6: 166-73.
8. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schrör K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353: 900.
9. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-8.
10. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schrör K, Hohlfeld T. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-7.
11. Kawasaki T, Ozeki Y, Igawa T, Kambayashi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000; 31: 591-5.
12. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107: 45-9.
13. Bierend A, Rau T, Maas R, Schwedhelm E, Böger RH. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease. Br J Clin Pharmacol 2008; 65: 540-7.
14. Karim S, Habib A, Lévy-Toledano S, Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 1996; 271: 12042-8.
15. Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997; 96: 1109-16.
16. Davì G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008-14.
17. Davì G, Neri M, Falco A, Festi D, Taraborelli T, Ciabattoni G, Basili S, Cuccurullo F, Patrono C. Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. Arterioscler Thromb Vasc Biol 2005; 25: 246-51.
18. 2α in three patients during sepsis, recovery and state of health. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 441-2.
19. Musiek ES, Yin H, Milne GL, Morrow JD. Recent advances in the biochemistry and clinical relevance of the isoprostane pathway. Lipids 2005; 40: 987-94.
20. 2α as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004; 109: 843-8.
21. 2 receptor in vivo. Circulation 2000; 101: 2833-40.
22. 2 receptor. Circ Res 2008; 103: 1037-46.
23. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol Lond 1963; 168: 178-95.
24. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, Chan CC. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 1996; 45: 68-74.
25. 1α in human urine. J Chromatogr A 2000; 885: 351-9.
26. Böger RH, Bode-Böger SM, Schröder P, Frölich JC. Increased prostacyclin production during exercise in untrained and trained men: effect of low-dose aspirin. J Appl Physiol 1995; 78: 1832-8.
27. 2α in human urine. J Chromatogr B 2000; 744: 99-112.
28. 2α. Possible methodological, mechanistic and clinical implications. J Chromatogr B 2003; 794: 237-55.
29. Krivosíková Z, Spustová V, Dzúrik R. A highly sensitive HPLC method for the simultaneous determination of acetylsalicylic, salicylic and salicyluric acids in biologic fluids: pharmacokinetic, metabolic and monitoring implications. Methods Find Exp Clin Pharmacol 1996; 18: 527-32.
30. 2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995; 332: 1198-203.
31. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002; 88: 711-5.
32. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-17.
33. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005; 46: 986-93.
34. 2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J Biol Chem 2006; 281: 4616-23.
35. 2α-III: evidence from apolipoprotein E- and LDL receptor-deficient mice. Circulation 2005; 112: 2867-74.
36. Kranzhofer R, Ruef J. Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX)1/2, a novel COX-1 polymorphism or the PIA(1/2) polymorphism. Platelets 2006; 17: 163-9.
37. Davì G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, Patrono C. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 2003; 107: 3199-203.
38. Goodwin DC, Gunther MR, Hsi LC, Crews BC, Eling TE, Mason RP, Marnett LJ. Nitric oxide trapping of tyrosyl radicals generated during prostaglandin endoperoxide synthase turnover. Detection of the radical derivative of tyrosine 385. J Biol Chem 1998; 273: 8903-9.
39. 2-isoprostanes predict cardiovascular mortality in postmenopausal women. J Clin Lipidol 2008; 2: 298-303.
40. 2-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. Am J Cardiol 2009; 104: 638-43.
41. Violi F, Pignatelli P, Basili S. Nutrition, supplements, and vitamins in platelet function and bleeding. Circulation 2010; 121: 1033-44.
42. Heitzer T, Baldus S, Schwedhelm E, Sydow K, Karstens M, Rudolph V, Tschentscher P, Meinertz T, Böger RH. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease. Evidence for anti-oxidant and anti-inflammatory effects. Arterioscler Thromb Vasc Biol 2006; 26: 1648-52.
43. 2 receptor, and activation of a separate cAMP-dependent inhibitory pathway in human platelets. Biochem Pharmacol 2008; 75: 2301-15.
44. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davì G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72: 1177-84.